DISCUSSION
In our previous work,7) we proposed that indomethacin produces a decrease in coronary blood flow and contractions of coronary arteries of dogs through inhibition of biosynthesis of endogenous prostaglandins, especially vasodilating prostaglandins such as prostaglandin E1 and/or prostacyclin. The present results indicate that SG-75 can depress the contractile responses of isolated dog coronary arterial strips to indomethacin. Since indomethacininduced contractions have been shown to be depressed by such drugs as arachidonate and phospholipase A2, which accelerate biosynthesis or release of prostaglandins,7) the depression of indomethacin-induced contractions by SG-75 may be related to a similar action. In fact, Neichi et al8) have reported that SG-75 increases the prostacyclin biosynthesis in a coupled system of rat platelets and pig aortic microsomes.
In the present study, tranylcypromine, an inhibitor of prostacyclin biosynthesis,9),10) could significantly depress only the relaxation induced by a 10-4Gm/ml dose of SG-75. This implies that SG-75 is only able to accelerate prostacyclin biosynthesis in coronary arteries at a dose of 10-4Gm/ml. The dose required in this experiment is consistent with that obtained from the biochemical data reported by Neichi et al.8) On the other hand, the present observations show that SG-75 depresses the indomethacin-induced contractions of coronary arteries at a dose of 10-5Gm/ml. It is plausible that this discrepancy in the dose levels (10-5Gm/ml versus 10-4Gm/ml) is caused by actions of SG-75 other than prostaglandin biosynthesis. At least two possible actions of SG-75 have been suggested: one is a nitroglycerin-like action,4),5) the another is an increase in potassium conductance.6) Therefore, it is rea- In conclusion, the present study indicates that SG-75 may produce coronary vasodilatation through activation of either intravascular prostacyclin biosynthesis or release from the tissues when large doses are given.
